Osilodrostat not checked

Novartis · LCI699

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
2 active
9 in total · 2 in the EU
Targets
 

What this is

How it works
Cortisol Synthesis Inhibitor FDA class
How it’s given
“Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical…”In the company’s words, NCT07247162 on ClinicalTrials.gov
Tested for
Cushing Syndrome (2 trials), Hypertension, Hypercortisolemia
Main trialPhase 4
“Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.”In the company’s words, NCT07247162 on ClinicalTrials.gov
Other names
isturisa · LCI699 · osilodrastat

Other drugs for Cushing Syndrome

All 3 drugs for Cushing Syndrome

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 4Recruiting May 2028 Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Phase 2Recruiting 21 Jul 2027 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Phase 3Completed 21 Feb 2018 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase 3Completed 19 Jun 2019 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Phase 2Completed 2 Jul 2009 A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
Phase 2Completed 12 Aug 2009 A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
Phase 2Completed 13 Oct 2009 A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
Phase 2Completed 22 Oct 2019 Safety and Efficacy of LCI699 in Cushing's Disease Patients
Phase 2Completed 16 Nov 2023 Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Osilodrostat

Following is part of Solo: you see every change to Osilodrostat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in